50 VCs that actually delivered | PitchBook News Summary

1. Key Themes

Outcome-Based VC Rankings Are Now Table Stakes

PitchBook has launched "The Syndicate," a data-driven league table ranking VC firms on actual investment outcomes rather than AUM or deal volume. The methodology is built on three measurable metrics: exit rate, follow-on rate, and valuation growth.

"Accel, Index Ventures and Sequoia are the top three firms in The Syndicate, a global ranking of venture capitalists based on the measurable outcomes of their investments from PitchBook data on each firm's deal and exit history."

"The global ranking shows the 50 top-performing firms out of the more than 37,000 venture capital firms we analyzed."

The GLP-1/Obesity Drug Gold Rush Is Over — Market Discipline Has Set In

The obesity drug investment wave, which drew massive capital from Big Pharma and private investors, has hit a saturation point. The market is now culling undifferentiated programs, and major pharma players are trimming pipelines.

"The gold rush led by Big Pharma and investors has ended. The market is punishing developers whose drugs fail to stand out, and pipelines are being trimmed. Pfizer just axed another program from its massive Metsera deal, while peers like Amgen have begun trimming their own early-stage pipelines."

"The next crop of targets looks a lot more like traditional, hard-nosed biotech investing: high risk, high upside, and no room for copycats."

Defense Tech Is an Active, Venture-Funded Category

Military AI is attracting serious early-stage capital, with Series B-level rounds going to companies building AI hardware and software specifically for the US defense sector.

"Smack Technologies, which develops AI software and hardware for the US military, raised a $61 million Series B led by Costanoa Ventures and First In, a defense-focused VC firm."

AI Infrastructure Is Still Drawing Unicorn-Level Early Funding

Low-power AI silicon hit a $1B+ valuation at Series A, signaling continued investor conviction in picks-and-shovels AI infrastructure plays.

"Velaura AI, a developer of low-power AI silicon and software, raised a $110 million Series A led by Seligman Ventures at a valuation of more than $1 billion."

PE Take-Privates and Secondary Sales Continue as LP Liquidity Pressure Grows

Institutional sellers are offloading PE stakes at a discount while PE firms continue to take listed companies private, underscoring an ongoing liquidity squeeze in the market.

"UC Investments sold $1 billion of private equity stakes to HarbourVest Partners, Bloomberg reported. The portfolio sold at a discount of over 10%."

"Francisco Partners has agreed to take NYSE-listed Weave Communications private for approximately $650 million."

2. Contrarian Perspectives

The Obesity Drug Opportunity Is NOT Over — It's Just Bifurcating

The consensus narrative is that obesity investing is crowded and declining. The contrarian read from PitchBook's analyst note is that the window is closing only for GLP-1 copycats — but differentiated, novel mechanisms remain genuinely high-upside bets.

"GLP-1 approaches—which drew the lion's share of investment—have hit a traffic jam. Late-arriving challengers face shrinking margins and clinical headwinds."

"The next crop of targets looks a lot more like traditional, hard-nosed biotech investing: high risk, high upside, and no room for copycats."

The implication: investors who abandoned the space entirely may miss the next wave of genuinely differentiated obesity biology plays.

China VC Exposure Has Effectively Gone to Zero Among Top Firms

While the narrative of US-China investment tension has been present for years, the actual numbers now show a near-complete withdrawal — not just a slowdown — from the largest PE/VC firms.

"The 10 biggest firms made no new China equity deals in 2026's first seven months, down from a dozen deals a year as recently as 2021. 'The juice may not be worth the squeeze,' says one industry leader."

This is a structural shift, not a cyclical one — suggesting that any emerging manager positioning around China access may find fewer strategic co-investors among the top tier.

De Beers' Confidence in the Face of Lab-Grown Diamond Disruption May Be Misplaced

De Beers' CEO claims to be "thrilled" about $12 lab-grown diamond studs at Walmart, framing the narrative as a bifurcating market. But spending hundreds of millions on a "natural is worth it" campaign while the price gap is 50x suggests a defensive posture, not strength.

"The old guard is spending hundreds of millions to convince you 'natural' is worth 50 times more than a lab-grown twin."

The contrarian view: mass-market commoditization of diamonds is accelerating, and brand-driven premiums face structural erosion regardless of marketing spend.

3. Companies Identified

Velaura AI Description: Developer of low-power AI silicon and software Why mentioned: Raised $110M Series A at $1B+ valuation — notable for unicorn status at Series A in AI infrastructure Quote: "a developer of low-power AI silicon and software, raised a $110 million Series A led by Seligman Ventures at a valuation of more than $1 billion."

Crusoe Description: Denver-based data center developer Why mentioned: Reportedly in IPO talks with at least four banks — a significant liquidity signal in the AI infrastructure space Quote: "Denver-based Crusoe, a data center developer, is in IPO talks with at least four banks, Axios reported."

Smack Technologies Description: Developer of AI software and hardware for the US military Why mentioned: Raised $61M Series B — a marquee example of the defense tech VC category gaining traction Quote: "which develops AI software and hardware for the US military, raised a $61 million Series B led by Costanoa Ventures and First In, a defense-focused VC firm."

Hopscotch Primary Care Description: Technology-enabled primary care provider serving rural communities Why mentioned: $53M Series D highlights continued investment in rural healthcare access Quote: "a technology-enabled primary care provider serving rural communities, raised a $53 million Series D led by 8VC and Townhall Ventures."

Abcuro Description: Massachusetts-based developer of immunotherapies for autoimmune diseases Why mentioned: $66M Series D in autoimmune — a growing area adjacent to the GLP-1/metabolic disease wave Quote: "a Massachusetts-based developer of immunotherapies for autoimmune diseases, raised a $66 million Series D led by New Leaf Venture Partners."

Craif Description: Japanese developer of urine-based cancer tests Why mentioned: $33M Series D — notable for non-invasive liquid biopsy approach in oncology diagnostics Quote: "a Japanese developer of urine-based cancer tests, raised a $33 million Series D."

Leal Therapeutics Description: Developer of therapies for central nervous system disorders Why mentioned: Eli Lilly participation in a $30M Series A extension signals pharma validation of the CNS pipeline Quote: "raised $30 million in a Series A extension with investment from Eli Lilly, OrbiMed and Newpath Partners."

Checkr Description: San Francisco-based AI verification company Why mentioned: Acquirer of Truv — consolidation signal in the employment/income verification space Quote: "San Francisco-based Checkr, an AI verification company, acquired Truv, an income and employment verification startup backed by Kleiner Perkins."

Cint Group Description: Market research/data company (previously publicly listed) Why mentioned: Dramatic valuation destruction — taken private at less than 1/10th of its 2021 peak, a stark cautionary tale on 2021-vintage valuations Quote: "valuing it at less than a tenth of the roughly $3 billion Cint commanded at its 2021 peak."

Ascensus Description: Provider of retirement plan services Why mentioned: Dual PE acquisition by Stone Point and Genstar Capital — signals consolidation in financial services infrastructure Quote: "Stone Point Capital and Genstar Capital have acquired equal stakes in Ascensus, a provider of retirement plan services."

Oceanloop Description: German developer of land-based aquaculture technology Why mentioned: Blended debt/equity financing from strategic and institutional investors including European Investment Bank — a model for climate/food tech capital stacks Quote: "raised up to €38.5 million ($44.5 million) in debt and equity from investors including Hatch Blue, Stolt Ventures and the European Investment Bank."

4. People Identified

Ben Zercher Description: Senior Research Analyst, Biotech & Pharma, PitchBook Why mentioned: Author of the obesity investing landscape analysis; mapped hundreds of clinical-stage programs by mechanism and stage Quote: "To track this crowded field, we mapped hundreds of clinical-stage obesity programs across development stages and biological mechanisms."

James Thorne & Jordan Rubio Description: PitchBook journalists Why mentioned: Authors of the VC league table coverage ("The Syndicate" rankings) Quote: "By James Thorne and Jordan Rubio"

Mark Walter & Todd Boehly Description: Co-owners of Chelsea FC Why mentioned: Reportedly considering selling stakes to Clearlake Capital — a notable sports asset liquidity event Quote: "Mark Walter and Todd Boehly are reportedly considering selling their stakes in Chelsea FC to Clearlake Capital."

Neena Nizar Description: Patient-advocate and sole clinical trial participant for an ultra-rare bone disease Why mentioned: Illustrates the extreme end of personalized medicine — lobbied for years to fund a trial and became its only patient Quote: "Neena Nizar spent years lobbying skeptical funders to get a trial for her ultra-rare bone disease off the ground. This summer, she became its sole patient."

5. Operating Insights

Differentiation is now the minimum bar in crowded biotech categories The obesity drug space is a live case study: once a biological mechanism becomes consensus, late entrants face structurally compressed margins and clinical risk without upside. The tactical lesson for biotech operators and investors is to pressure-test your mechanism's novelty before committing to a crowded pathway.

"The market is punishing developers whose drugs fail to stand out, and pipelines are being trimmed."

Outcome metrics — not activity metrics — are what LPs and co-investors are now tracking The launch of PitchBook's Syndicate rankings based on exit rate, follow-on rate, and valuation step-ups signals a broader shift in how GP performance will be evaluated. For fund managers, this is a call to instrument and communicate outcomes, not just deal flow.

"Each firm receives a score based on three measures of investment performance since 2010. The first is exit rate... The second is follow-on rate... The third is valuation growth."

Rural healthcare remains a durable, capital-attracting vertical Despite healthcare's overall funding volatility, tech-enabled primary care serving underserved rural markets continues to attract significant late-stage capital. Operators in this space have a clear fundraising narrative tied to access and cost.

"Hopscotch Primary Care, a technology-enabled primary care provider serving rural communities, raised a $53 million Series D led by 8VC and Townhall Ventures."

6. Overlooked Insights

Sovereign wealth funds are quietly anchoring new Asia-focused vehicles Kembangan Capital's $725M fund — anchored by an anonymous sovereign wealth fund — allocates $500M to fund-of-funds and the remainder to direct/co-investments. This structure suggests sovereign capital is re-entering Asian PE/VC through intermediary vehicles rather than direct deployment, a potentially underappreciated LP trend.

"The fund, anchored by an anonymous sovereign wealth fund, will reserve $500 million for fund-of-fund investments and the remaining for direct and co-investments."

Lower-middle-market manufacturing is attracting fresh debut fund capital Broadwing Capital Management raised $440M for its debut fund focused specifically on lower-middle-market manufacturing and services — a segment often overlooked in favor of tech-forward PE. This signals growing conviction that operational value creation in industrial businesses remains attractive in the current environment.

"Broadwing Capital Management raised $440 million for its debut fund to invest in lower-middle-market manufacturing and services companies."